Q3 2019 Investor Presentation

ResMed + Propeller = platform for entire patient journey Total Addressable Market: ~380 million patients¹ Global COPD population COPD progression ResMed Propeller zz 75% of TAM Stage I Stage II 1. Source: https://www.ncbi.nlm.nih.gov/pubmed/26755942 © 2019 ResMed I Q3 2019 Investor Presentation | 24 Increasing severity of disease Self-management & Smoking Cessation Inhaled Medications 20% of TAM Supplementary 02 Ventilation <1% of TAM Stage III Stage IV ResMed

View entire presentation